Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879952 | 0.79 | CYP3A4 (0.35) | CYP3A4MAPTRECQL | |
| SCHEMBL18237168 | 0.79 | CYP3A4 (0.35) | CYP3A4MAPTRECQL | |
| SCHEMBL15874150 | 0.78 | — | — | |
| SCHEMBL18835579 | 0.72 | UGT2B7 (0.33) | CYP3A4MAPTRECQL | |
| SCHEMBL14879887 | 0.72 | UGT2B7 (0.33) | CYP3A4MAPTRECQL | |
| SCHEMBL14879886 | 0.72 | UGT2B7 (0.33) | CYP3A4MAPTRECQL | |
| SCHEMBL11797090 | 0.69 | PTPN1 (0.35) | CYP3A4MAPTRECQL | |
| SCHEMBL31410914 | 0.69 | PTPN1 (0.35) | CYP3A4MAPTRECQL | |
| Methane SCHEMBL28757480 | 0.68 | PTPN1 (0.34) | CYP3A4MAPTRECQL | |
| SCHEMBL14879850 | 0.68 | SMN1; SMN2 (0.37) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-9937167-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-20170224682-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9540353-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2017-01-10 | — | — | US | disclosed |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| EP-2943470-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272081-B2 | SHIP1 modulators and methods related thereto | PPP1R1B, PPM1A, PPM1D | CYP3A4 4531/4885MAPT 4687/4885RECQL 238/4885 |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1A, PPM1D, PPP1R1B | CYP3A4 4581/4885MAPT 4623/4885RECQL 294/4885 |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | CYP3A4 4531/4885MAPT 4687/4885RECQL 238/4885 |
| US-20170224682-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | CYP3A4 4531/4885MAPT 4687/4885RECQL 238/4885 |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | CYP3A4 4531/4885MAPT 4687/4885RECQL 238/4885 |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | CYP3A4 4531/4885MAPT 4687/4885RECQL 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.